Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
(TRENT Trial)
Recruiting in Palo Alto (17 mi)
+75 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Sanofi
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This trial compares two insulin treatments, Gla-300 and IDeg-100, in patients with Type 2 Diabetes who have kidney issues and haven't used insulin before. The goal is to see which insulin better controls blood sugar without increasing the risk of low blood sugar. Gla-300 is a long-acting insulin with improved profiles compared to Gla-100 and IDeg-100.
Research Team
Eligibility Criteria
Inclusion Criteria
Do you have kidney failure?
You are able to use an electronic diary to record your experiences and agree to follow the study's rules.
You are 18 years old or older at the time of the screening.
See 7 more
Treatment Details
Interventions
- Insulin degludec 100 U/mL (Long-acting Insulin)
- Insulin glargine 300 U/mL (Long-acting Insulin)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Gla-300 armExperimental Treatment1 Intervention
Gla-300 will be administered once daily for 24 weeks
Group II: IDeg-100 armActive Control1 Intervention
Ideg-100 will be administered once daily for 24 weeks
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sanofi
Lead Sponsor
Trials
2,246
Recruited
4,085,000+
Paul Hudson
Sanofi
Chief Executive Officer since 2019
Degree in Economics from Manchester Metropolitan University
Christopher Corsico
Sanofi
Chief Medical Officer
MD from Cornell University, MPH in Chronic Disease Epidemiology from Yale University